Cancer-related inflammation and treatment effectiveness (Q38256601)

1 September 2017

1 reference

title

Cancer-related inflammation and treatment effectiveness (English)

1 reference

1 September 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25281468%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Donald C McMillan

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25281468%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Stephen Clarke

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25281468%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Kellie A Charles

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25281468%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

1 October 2014

1 reference

Lancet Oncology Commission

1 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25281468%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25281468%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25281468%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

e493-503

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25281468%20AND%20SRC:MED&resulttype=core&format=json

Hallmarks of Cancer: The Next Generation

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Pathological findings from the national surgical adjuvant breast project (protocol no. 4). IV. Significance of tumor necrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Inflammasomes in cancer: a double-edged sword

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Inflammasomes: far beyond inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Inflammasome: cancer's friend or foe?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

IL-18 Induces PD-1-Dependent Immunosuppression in Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Cytokines as a key component of cancer-related inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Coordinated regulation of myeloid cells by tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Activation of vascular endothelial growth factor receptor-2 in bone marrow leads to accumulation of myeloid cells: role of granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Neutrophil differentiation from human‐induced pluripotent stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

NF-κB and the link between inflammation and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Inflammation and oncogenesis: a vicious connection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Inflammation and prognosis in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

The systemic inflammatory response and its relationship to pain and other symptoms in advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

A systematic review of the association between circulating concentrations of C reactive protein and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

C-reactive protein and colorectal cancer risk: a systematic review of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

C-reactive protein as a biomarker for urological cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Monocyte recruitment during infection and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Myeloid-derived suppressor cell heterogeneity and subset definition.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Tumoricidal activity of human dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Terminology in cancer cachexia: importance and status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Cancer and systemic inflammation: treat the tumour and treat the host

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

IκBKβ and NFκB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Anti-inflammatory effects of statins: clinical evidence and basic mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Statins as a newly recognized type of immunomodulator

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Cancer and the tumor microenvironment: a review of an essential relationship

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Interleukin-6 as a therapeutic target in human ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Targeting of the innate immunity/inflammation as complementary anti-tumor therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Chemokines, chemokine receptors and small-molecule antagonists: recent developments

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Seeing the future of cancer-associated transcription factor drug targets

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Investigational Janus kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Therapeutic cancer vaccines: past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Dendritic-cell-based therapeutic cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Modulation of immunity by antiangiogenic molecules in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Targeting immune suppressing myeloid-derived suppressor cells in oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970263-3

7 January 2021

10.1016/S1470-2045(14)70263-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25281468%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference